How Would Affy s Patent Fare if the US Adopted an Opposition System? | GenomeWeb

Now that one of Affy’s patents has been revoked — however temporarily — in Europe, companies like CombiMatrix and Applera may see the EPO as a more attractive route for opposing patents, rather than taking up the matter in the litigation-friendly US.

According to CombiMatrix’ CEO Amit Kumar, his firm has no plans to oppose any of Affymetrix’ US patents, unless the US moves to a system similar to one used in Europe and Japan that incorporates opposition into the format of granting patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.